Innovation in this sector is driven by a handful of global leaders specializing in immunology and rare diseases. A review of the Immune Thrombocytopenia Market Share highlights companies like Amgen, Novartis, and Sobi as dominant forces, particularly due to their successful TPO-RA portfolios. Competitive pressure is mounting, however, as new entrants bring orally available SYK inhibitors to...